The most hopeful cancer news in years
Oncologists at the 2026 ASCO meeting gave a standing ovation to clinical trial results showing that the drug daraxonrasib significantly improved survival rates for advanced pancreatic cancer. This development is being hailed as a major breakthrough for a historically treatment-resistant disease.
Why it matters
Pancreatic cancer has one of the lowest survival rates of all cancers, making this potential treatment a significant advancement in medical science.
Why a roomful of oncologists gave a standing ovation for a line graph.
The report focuses on scientific data and the professional reaction of the medical community without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in